Zealand Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was DKK 295.52 million compared to DKK 43.71 million a year ago. Net income was DKK 74.15 million compared to net loss of DKK 148.34 million a year ago. Basic earnings per share from continuing operations was DKK 1.27 compared to basic loss per share from continuing operations of DKK 3.29 a year ago. Diluted earnings per share from continuing operations was DKK 1.23 compared to diluted loss per share from continuing operations of DKK 3.29 a year ago. Basic earnings per share was DKK 1.27 compared to basic loss per share of DKK 3.21 a year ago. Diluted earnings per share was DKK 1.23 compared to diluted loss per share of DKK 3.21 a year ago.
For the nine months, sales was DKK 319.55 million compared to DKK 80.06 million a year ago. Net loss was DKK 438.99 million compared to DKK 859.69 million a year ago. Basic loss per share from continuing operations was DKK 7.84 compared to DKK 14.46 a year ago. Diluted loss per share from continuing operations was DKK 7.84 compared to DKK 14.46 a year ago. Basic loss per share was DKK 7.84 compared to DKK 19.28 a year ago. Diluted loss per share was DKK 7.84 compared to DKK 19.28 a year ago.